On Monday, January 13, 2020, the PLGG/PLGA (Pediatric Low-Grade Glioma/Astrocytoma) Coalition kicked off their fourth meeting in six years to discuss the latest scientific studies and best practices in clinical trials for treating PLGA patients. The coalition’s goal is to accelerate the pace of PLGA research by finding common ground for evaluating and treating PLGA patients, as well as identifying the scientific direction to better understand low-grade tumors and target them for eradication. This conference has been a catalyst for the most prolific period of PLGA research to date.
Over two days in Ladenburg, Germany, the group discussed a range of important topics including Classifying PLGG within the World Health Organization Coding System, Non-BRAF Tumor Biology, Creating a PLGG Model System, Oncogene Induced Senescence and Micro-Environment, Clinical Trial Updates, the Next Generation of Clinical Trials, and more.
36 leading researchers and clinicians convened from seven countries and 19 research institutions including The Dana-Farber Cancer Institute, University College of Queens (UK), Children’s National Medical Center, Cincinnati Children’s Hospital, Sick Kids (Toronto), Research Institute of McGill Medical, and Washington University of Saint Louis Medical Center. Their collaborative efforts are shaping the future for treating PLGA patients and giving hope to them and their families.
Pediatric Brain Tumor Foundation Celebrates FDA Approval of Day One Biopharmaceuticals’ OJEMDA™, New Treatment for Common Pediatric Brain Tumor Type
The Pediatric Brain Tumor Foundation is pleased to celebrate the FDA’s approval of Day One Biopharmaceuticals’ OJEMDA (tovorafenib), a new therapy for the treatment of pediatric low-grade glioma (pLGG), the most common brain tumor diagnosed in children. The FDA’s approval of OJEMDA represents a significant milestone for pLGG patients and their families. The new treatment also stands as a key breakthrough in the Pediatric Brain Tumor Foundation’s efforts to accelerate new treatment options for all children with brain tumors.
Pediatric Brain Tumor Foundation Awards More Than $1 Million in New Research Funding to Dana-Farber Cancer Institute
The Pediatric Brain Tumor Foundation (PBTF) proudly announces an infusion of $1 million to help researchers, led by Dana-Farber Cancer Institute’s Drs. Pratiti (Mimi) Bandopadhayay and Rameen Beroukhim, launch a study into a novel therapeutic target and expand their research into overcoming treatment resistance and rebound growth.
